top of page

Latest News

12.6.25

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Registry study confirms cilta-cel’s superior outcomes in real-world multiple myeloma treatment

Read More
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

2.5.25

Final episodes of the AI Act video series now available

New videos complete explainer series on EU AI regulation

Read More
Final episodes of the AI Act video series now available

30.4.25

Predicting progression events in multiple myeloma from routine blood work

Machine learning model anticipates disease trajectories to support early intervention and personalised care

Read More
Predicting progression events in multiple myeloma from routine blood work

13.3.25

CERTAINTY annual meeting 2025 gathers project partners in Paris

Two-day hybrid event convenes partners for scientific exchange, project updates, and strategic alignment

Read More
CERTAINTY annual meeting 2025 gathers project partners in Paris

21.2.25

Rare case of T cell lymphoma post-CAR T therapy uncovered through multiomic profiling

Study provides insights into clonal evolution following CAR T and bispecific antibody treatment in multiple myeloma

Read More
Rare case of T cell lymphoma post-CAR T therapy uncovered through multiomic profiling
Key visuals (2).png

© Artur - stock.adobe.com / Fraunhofer IZI

© 2026 by Collaborate Project Management GmbH.

  • LinkedIn
  • Youtube

CONTACT
CERTAINTY

For further information on the CERTAINTY project, feel free to contact us through email or keep up with our latest updates by following our social media channels.  

 

Email: info@certainty-virtualtwin.eu

Funded by the European Union Logo

This project was funded by the European Union under Grant Agreement number 101136379. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.

Terms of use

Privacy

Impressum

bottom of page